BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

GW Pharmaceuticals Ltd. 

Porton Down Science Park

Salisbury  Wiltshire  SP4 0JQ  United Kingdom
Phone: 44-1980-619000 Fax: +44-1980-619111


SEARCH JOBS

View Clinical Trials from BioPharm Insight



Industry
Pharmaceutical






 Company News
GW Pharmaceuticals Reports 2014 Third Quarter Financial Results 8/6/2014 7:55:05 AM
GW Pharmaceuticals To Report Q3 2014 Financial Results And Host Conference Call On 6 August, 2014 7/30/2014 9:08:06 AM
GW Pharmaceuticals Announces The Closing Of U.S. Public Offering Of American Depositary Shares (Adss) Totaling Approximately $169.8 Million On The NASDAQ Global Market And Full Exercise Of Underwriters' Option To Purchase Additional Adss 6/26/2014 7:41:40 AM
GW Pharmaceuticals Eyes $148 Million In NASDAQ Offering 6/19/2014 6:17:37 AM
GW Pharmaceuticals Announces Proposed Public Offering Of ADSs 6/18/2014 8:44:39 AM
GW Pharmaceuticals Announces Physician Reports Of Epidiolex®: Treatment Effect In Children And Young Adults With Treatment-Resistant Epilepsy From Physician-Led Expanded Access Treatment Program 6/17/2014 10:38:10 AM
GW Pharmaceuticals Announces Epidiolex® Receives Fast Track Designation From FDA For The Treatment Of Dravet Syndrome 6/6/2014 9:31:54 AM
GW Pharmaceuticals Announces Agreement With New York State To Investigate Use Of CBD To Treat Medication-Resistant Epilepsies In Children 6/4/2014 12:18:15 PM
GW Pharmaceuticals Receives Investigational New Drug (IND) From FDA For Phase 2/3 Clinical Trial Of Epidiolex® In The Treatment Of Dravet Syndrome 5/7/2014 9:17:17 AM
GW Pharmaceuticals Reports Second Quarter 2014 Financial Results and Operational Progress 5/7/2014 9:01:01 AM
12345678910...